Miriam Koopman

May 20, 2024 | nature.com | Miriam Koopman |Petur Snaebjornsson

AbstractEncorafenib-cetuximab has been approved for pretreated BRAFV600E-mutated metastatic colorectal cancer (mCRC) patients based on efficacy demonstrated in the randomized phase III BEACON trial. The aim of this real-world effectiveness study is to improve knowledge on the generalizability of trial results. This population-based real-world study includes all mCRC patients in the Netherlands treated with encorafenib-cetuximab since approval.

Oct 23, 2023 | healio.com | Mark Leiser |Mindy Valcarcel |Marwan Fakih |Miriam Koopman

You've successfully added Hematology Oncology: Gastrointestinal Cancer to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Sotorasib plus panitumumab extended PFS compared with standard care. Grade 3 or higher adverse events occurred less frequently with the combination.